Singapore markets closed

Sesen Bio, Inc. (SESN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.7061-0.0129 (-1.79%)
At close: 04:00PM EST
0.7050 -0.00 (-0.16%)
Pre-market: 04:22AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.7190
Open0.7080
Bid0.0000 x 900
Ask0.0000 x 800
Day's range0.7000 - 0.7296
52-week range0.7000 - 6.0400
Volume2,129,238
Avg. volume6,724,008
Market cap140.842M
Beta (5Y monthly)0.56
PE ratio (TTM)N/A
EPS (TTM)-0.1470
Earnings date14 Mar 2022 - 18 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.25
  • Business Wire

    Sesen Bio Further Enhances Team with Key Hires

    CAMBRIDGE, Mass., January 10, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.

  • Motley Fool

    Why Sesen Bio Stock Got Slammed Today

    The biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). In its press release published just after the meeting, which Sesen Bio characterized as "productive," the company wrote that it now "believes it has greater clarity regarding the requirements for resubmission of the BLA and the trial design."

  • Business Wire

    Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™

    CAMBRIDGE, Mass., December 09, 2021--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its anticipated regulatory path forward for Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).